Bundesrepublik Deutschland Ietzvertreten durch das Robert Koch-Institut vertreten durch seinen Präsi
发明人:
Richard KROCZEK
申请号：
US15126487
公开号：
US20170087232A1
申请日:
2015.03.17
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates to a medicament for use in a method of extending a cellular cytotoxic immune response against an antigen-comprising protein, the method comprising the step of: i) administering to a patient having T cells activated against an antigen a peptide-loaded major histocompatibility complex class I (MHC-I) presenting cell and an adjuvant which supports a Th-1-mediated response, wherein the peptide is derived from the antigen-comprising protein, thereby re-activating the activated T cell, wherein the peptide-loaded major histocompatibility complex class I (MHC-I) presenting cell of step i) is administered in a time frame of from 0 h to 14 days after the T cells were activated against an antigen.
